ClinicalTrials.gg
TerminatedNCT02910115Updated Jan 26, 2026

Cooling the Uterus in C-section After Dysfunctional Labor

An interventional study of Cold laparotomy sponges and Pitocin in Blood Loss, Dysfunctional Labor and Uterine Atony, sponsored by Baylor Research Institute. Terminated. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Baylor Research Institute · Not applicable, Interventional, and Prevention

Why this study was terminated
Difficulty in acquiring patients in a reasonable amount of time.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2015, registered Jan 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The objective of the study is to demonstrate whether cooling the uterine smooth muscle during cesarean section (following delivery of the fetus) will promote better uterine contraction and involution resulting in lower blood loss, use of fewer uterotonic medications, and fewer hysterectomies following cesarean section for dysfunctional labor.

Read the detailed description

Two hundred patients will be drawn from all pregnant women who require a cesarean delivery for dysfunctional labor. Dysfunctional labor will be defined as cervical dilation of 3 or more centimeters, in active labor without cervical change for 2 or more hours. Patients will be randomly assigned to the study group or the control group, and each group will have 100 patients.

Following the delivery of the fetus, patients in the control group will have IV Pitocin administered per the usual protocol and the uterus will be wrapped in lab sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. Additional utero-tonic medications may be given to improve uterine contraction.

In the study group, following the delivery of the fetus, the uterus will be externalized in the usual fashion, except the uterus will be wrapped with lap sponges saturated in sterile, iced normal saline. Additional utero-tonic medications may also be given in the study group to improve uterine contraction.

Immediately after the delivery of the fetus and prior to the delivery of the placenta, the amniotic fluid and blood on the surgical field will be aspirated into the suction canister. This amount of fluid in the suction canister will be noted and subtracted from the amount of fluid in the canister at the conclusion of the surgery.

At the conclusion of the surgery, blood loss will be calculated by measuring the content of blood in the suction canister, and by weighing the surgical sponges. Post surgical vaginal bleeding will be monitored and calculated until the patient is discharged from the labor and delivery unit. Use of utero-tonic medications will be recorded.

At the conclusion of the study, the amount of blood loss and utero-tonic drugs between the control and study groups will be compared. The need for additional surgeries, such as a hysterectomy or D\&C, will be compared between the two groups.

02

Conditions studied

  • Blood Loss
  • Dysfunctional Labor
  • Uterine Atony
03

In context

Hemorrhage

1,383 studies on the registry are indexed under Hemorrhage; 244 are open to participants now.

This study's enrollment of 8 is below the median of 102 across 926 interventional studies indexed under Hemorrhage.

Browse Hemorrhage studies →

Lead sponsor

Baylor Research Institute is the lead sponsor of 223 studies on the registry; 48 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 9 (39%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pregnant women of any age
  • gravidity and gestational duration who present for cesarean section and who have given to be in the study.

Exclusion criteria

Exclusion criteria:

  • Women who refuse to be in the study
  • women who are unable to consent due to emergent nature of the cesarean section
  • women who are unable to understand the nature of the study due to mental illness, mental retardation, medical condition, or other communication barrier will be excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
8 participants (actual)

Study arms

  • Other
    Control Group

    Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.

    Drug: Pitocin

  • Experimental
    Study Group

    Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol. Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician.

    Other: Cold laparotomy sponges · Drug: Pitocin

Interventions

  • OtherCold laparotomy sponges

    Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline

    Also known as: cold lap sponges

  • Pitocin is administered intravenously according to the usual protocol.

    Also known as: IV Oxytocin

06

What researchers measure

Primary outcomes

  1. Estimated Blood Loss

    Time frame: up to 24 hours after surgery

Secondary outcomes

  1. Change in Hematocrit

    Time frame: up to 24 hours after surgery

  2. Need for use of uterotonic medications

    Time frame: during cesarean section

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02910115
Responsible party
Sponsor
First posted
Sep 21, 2016
Start date
May 14, 2015
Primary completion
Nov 10, 2017
Completion
Nov 10, 2018
Last update
Jan 26, 2026

Study contacts

Jack Stecher, MD
principal investigator · BUMC Labor and Delivery

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion